Abstract
Long term treatment of venous thromboembolism is essential to complete therapy of the index episode and to reduce recurrences. Vitamin K antagonists are the mainstay for the long term treatment of venous thromboembolism for the majority of the patients as they allow oral administration. Low-molecular weight heparins are recommended for the long term treatment of cancer patients. The duration of long term anticoagulation depends on the features of the index venous thromboembolism and on the presence of associated risk factors. Patients at high risk for recurrence – mainly those who suffered unprovoked venous thromboembolism and those with cancer – should be evaluated for extended anticoagulation. The risk for major bleeding complications and the inconvenience for monitoring, dose adjustment and drug-food interactions are the main constraints for indefinite anticoagulant treatment. New anticoagulants with more favourable efficacy- safety profile and reduced need for monitoring could improve the feasibility of extended anticoagulation.
Keywords: Venous thromboembolism, vein thrombosis, pulmonary embolism, anticoagulants.
Current Vascular Pharmacology
Title:Long-term Treatment of Venous Thromboembolism
Volume: 12 Issue: 3
Author(s): Cecilia Becattini and Giorgia Manina
Affiliation:
Keywords: Venous thromboembolism, vein thrombosis, pulmonary embolism, anticoagulants.
Abstract: Long term treatment of venous thromboembolism is essential to complete therapy of the index episode and to reduce recurrences. Vitamin K antagonists are the mainstay for the long term treatment of venous thromboembolism for the majority of the patients as they allow oral administration. Low-molecular weight heparins are recommended for the long term treatment of cancer patients. The duration of long term anticoagulation depends on the features of the index venous thromboembolism and on the presence of associated risk factors. Patients at high risk for recurrence – mainly those who suffered unprovoked venous thromboembolism and those with cancer – should be evaluated for extended anticoagulation. The risk for major bleeding complications and the inconvenience for monitoring, dose adjustment and drug-food interactions are the main constraints for indefinite anticoagulant treatment. New anticoagulants with more favourable efficacy- safety profile and reduced need for monitoring could improve the feasibility of extended anticoagulation.
Export Options
About this article
Cite this article as:
Becattini Cecilia and Manina Giorgia, Long-term Treatment of Venous Thromboembolism, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/157016111203140518154040
DOI https://dx.doi.org/10.2174/157016111203140518154040 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.
Current Vascular Pharmacology The Successful Treatment of Pulmonary Embolism as a Complication after Uterine Fibroid Embolization (Case Report)
Current Women`s Health Reviews Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Thrombolytic Therapy in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Perioperative Safety of Warfarin Therapy and Reversal
Current Drug Safety Potential Pharmacological Applications of the Antithrombotic Molecule High Molecular Weight Kininogen
Current Vascular Pharmacology Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research